Scarica l'app Stockscreener
16.75
0.39%
0.065
Dopo l'orario di chiusura:
16.82
0.065
+0.39%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SMMT Giù?
Forum
Previsione
Summit Therapeutics Inc Borsa (SMMT) Ultime notizie
Barclays Maintains Summit Therapeutics(SMMT.US) With Hold Rating, Raises Target Price to $20 - Moomoo
Summit Therapeutics Stock Climbs Wednesday: What's Happening? - Benzinga
AstraZeneca's $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets - 247wallst.com
Leerink Partners Sticks to Its Hold Rating for Summit Therapeutics (SMMT) - theglobeandmail.com
Wells Fargo Reaffirms Their Buy Rating on Summit Therapeutics (SMMT) - theglobeandmail.com
AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up - reuters.com
AstraZeneca Places a $2B Bet on a Summit Therapeutics Cancer Drug - MedCity News
AstraZeneca's $2 Billion Investment in Summit Therapeutics Seen as 'Win-Win,' UBS Says - marketscreener.com
SMMT Stock Jumps As AstraZeneca Backs Ivonescimab Bet - StocksToTrade
Summit Therapeutics Rises as AstraZeneca Backs Ivonescimab With $2 Billion Investment - Quiver Quantitative
Summit Therapeutics: Stronger Balance Sheet Helps, But It Does Not De-Risk Ivonescimab - Seeking Alpha
How Summit Therapeutics Stock Could Surge 162% After AstraZeneca Investment - Barron's
Roundup: Hengrui Pharma and Novo Enter Exclusive License Agreement for HRS-1596, AstraZeneca Enters Collaboartion with Summit Therapeutics - Pharmaceutical Executive
Summit Therapeutics Stock Jumps On $2B AstraZeneca Deal - timothysykes.com
AstraZeneca Invests in Summit Therapeutics after Year of Speculation - Benzinga
AstraZeneca Invests $2B in Summit for Cancer Drug Dev - Rediff MoneyWiz
Summit Therapeutics Stock Jumps On $2B AstraZeneca Deal And Trial Wins - StocksToTrade
Summit Therapeutics Inc. (SMMT) stock price, news, quote and history - Yahoo Finance Australia
Summit Therapeutics Soars On $2B AstraZeneca Bet And Trial Wins - StocksToTrade
Summit Therapeutics Soars Nearly 20% After AstraZeneca Bets $2 Billion on Cancer Drug Ivonescimab - Benzinga
Form 8K Summit Therapeutics PLC ADR For: 29 September By Investing.com - Investing.com Nigeria
AstraZeneca to invest $2bn in Summit for ADC combination therapies - Yahoo Finance
Goldman Sachs reiterates Summit Therapeutics stock rating on AstraZeneca deal - Investing.com Canada
Summit Therapeutics Shares Rise 22% After $2 Billion AstraZeneca Investment - Yahoo Finance
Summit soars after $2 billion investment from AstraZeneca for cancer therapies - reuters.com
Summit Therapeutics Raises $2.0 Billion in Convertible Preferred Private Placement With AstraZeneca - TradingView
AMD, Nvidia, Navitas, Summit Therapeutics, Fair Isaac, and More Stocks That Explain Today's Market -- Barrons.com - Moomoo
AstraZeneca invests $2bn in Summit Therapeutics - marketscreener.com
AstraZeneca announces strategic equity investment and clinical collaboration with Summit Therapeutics to advance leading ADC combination strategy in cancer - Cambridge Network
AstraZeneca invests $2bn in Summit Therapeutics to develop cancer drug - Business Weekly
AstraZeneca invests $2B in Summit Therapeutics for ADC trials By Investing.com - Investing.com Australia
Summit Therapeutics Inc. stock jumps on AstraZeneca’s $2B deal, but chart stays weak - The Cryptonomist
AstraZeneca invests $2 billion in Summit Therapeutics in cancer drug deal - Proactive financial news
Summit Therapeutics agrees to US$2B AstraZeneca equity investment - Mugglehead Investment Magazine
AstraZeneca invests $2 billion in Summit Therapeutics By Investing.com - Investing.com South Africa
Summit Therapeutics (SMMT) Secures $2B AstraZeneca Investment, S - GuruFocus
Update: Summit Therapeutics Shares Jump as AstraZeneca's Plan to Invest $2 Billion - Yahoo Finance
AstraZeneca to invest USD2 billion in Summit Therapeutics - marketscreener.com
AstraZeneca to Invest $2 Billion in Summit Therapeutics, Collaborate on Cancer Drugs - WSJ
Summit shares surge after-hours on $2 billion AstraZeneca equity deal - Yahoo Finance
Summit Therapeutics rises after AstraZeneca commits $2B investment - TradingView
Summit Therapeutics Jumps on $2 Billion AstraZeneca Deal - Bloomberg.com
AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics - Business Wire
Summit Therapeutics Inc. announced that it expects to receive $2 billion in funding from AstraZeneca PLC - marketscreener.com
Bernstein Reaffirms Their Hold Rating on Summit Therapeutics (SMMT) - The Globe and Mail
SMMT Stock Gains After Summit Reports Strong Lung Cancer Survival Results — Investors Await Q2 Earnings - stocktwits.com
Why Is SMMT Stock Tumbling Today? - stocktwits.com
Summit Therapeutics Inc. (SMMT) Stock Price, News, Quote & History - Yahoo! Finance Canada
Summit Therapeutics plc (SMMT) stock price, news, quote and history - Yahoo Finance UK
Summit Therapeutics Inc. (SMMT) latest stock news and headlines – Yahoo Finance - Yahoo Finance Singapore
SMMT News | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill
Cantor Fitzgerald reiterates Overweight on Summit Therapeutics stock By Investing.com - Investing.com Nigeria
HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at ESM - BioSpace
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):